Efficacy of Sugammadex in reversal of Rocuronium versus Vecuronium induced Neuromuscular Blockade - a randomized controlled double blind trial

This randomized study aims to evaluate the efficacy of sugammadex in reversing neuromuscular block induced by rocuronium versus vecuronium in adult patients undergoing elective surgery under general anesthesia. Neuromuscular blockade is routinely achieved using steroidal agents such as rocuronium and vecuronium, and reversal is traditionally done with neostigmine, which carries risks of incomplete recovery and adverse effects. Sugammadex, a novel  gamma cyclodextrin, offers rapid and predictable reversal by encapsulating these agents, with a higher binding affinity for rocuronium. Patients will be randomized into two groups Group R which is rocuronium with sugammadex and Group V which is  vecuronium with sugammadex. The primary outcome is time to recovery of train-of-four ratio greater than 0.9. Secondary outcomes include hemodynamic stability and adverse effects. The results may guide anesthesiologists in optimizing the choice of neuromuscular blocking agent when sugammadex is planned for reversal.